Answers are grounded in this paper and cite their sources.
Recent legislation directs the FDA to consider how best to use real-world evidence to ensure device safety and effectiveness while accelerating access to new technologies. But rigorous observational statistical methods are needed to mitigate limitations of such data.
No takes yet. Share an insight, caveat, or question.
Resnic et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: